Both patients in our study with a JAK2 V617F mutation also responded, extending prior observations that reported 3/4 responses in patients with JAK2-positive myelofibrosis treated with panobinostat.16 The ability of panobinostat to target JAK2 mutant bone marrow disease provides some rationale for combining this drug with JAK2 inhibitors in future studies. The gene discussed is JAK2; the disease is bone marrow disorder.